Gene expression profiling of MDA-MB-231 cells treated Compound 28, a CDK9 degrader

Triple-negative breast cancer (TNBC) is highlyaggressive with very limited treatment options due to the lack of efficient targeted therapies and thus still remains clinically challenging. Targeting CDK9 to remodel transcriptional regulation shows great promisein cancer therapy. We synthesized new series of heterobifunctional molecules ashighly selective and efficacious CDK9 degraders, enabling potentinhibition of TNBC cell growth and rapidly targeted degradationof CDK9. Moreover, the CDK9 degrader (compound 28) was used to treat on TNBC cell lines and the gene expression profile was performed by RNA-seq. MDA-MB-231 cell line were seed into 6 well plate at densities of 5×105 cells/well, the culture medium was replaced 24 h later, and MDA MB 231 cell line were incubated with 500 nM of 28 for 4 h, then the RNA of the cell line is extracted for RNA-seq.